neuroClues Secures €10M to Advance AI-Powered Parkinson’s Diagnosis in U.S. and Europe
neuroClues, a French-Belgian medtech company, has raised €10 million in a Series A funding round to support the development and commercialization of its AI-powered eye-tracking device for early diagnosis of neurological disorders, including Parkinson’s disease. The device uses a portable headset to capture infrared images of eye movements, extracting biomarkers that can indicate neurological conditions years before symptoms appear. Having received CE certification in January 2025, neuroClues is now targeting FDA clearance in the United States by 2026. The funding will be used to expand the company’s commercial team and operations in European and U.S. markets. The device aims to address the diagnostic gap in Parkinson’s disease, where early detection is crucial for effective treatment. 
